Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2989-2996

  Benelli, Roberto ^a   Monteghirfo, Stefano ^a   Balbi, Cecilia ^a   Barboro, Paola ^a   Ferrari, Nicoletta ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis; Angiotensinogen; hnRNP K; Metronomic chemotherapy; Prostate carcinoma

Indexed keywords

ANGIOGENESIS INHIBITOR; DOCETAXEL; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; SMALL INTERFERING RNA; TAXOID; THROMBOSPONDIN 1;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; UPREGULATION; CANCER INVASION; CELL MOTION; CHEMOTAXIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTAXIS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TAXOIDS; THROMBOSPONDIN 1; TUMOR CELLS, CULTURED;

EID: 65649100065     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24305     Document Type: Article

References (37)

1. Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target. Chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206 (Pubitemid 32176298)
2. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886 (Pubitemid 30207647)
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047 (Pubitemid 30217688)
4. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-4155
5. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943 (Pubitemid 35424084)
6. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-19 (Pubitemid 36177350)
7. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104:121-129 (Pubitemid 36184155)
8. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 1999;26:32-36 (Pubitemid 29340755)
9. Rose WC, Fairchild C, Lee FY. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001;47:97-105. (Pubitemid 32662313)
10. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-3245 (Pubitemid 17082655)
11. Albini A, D'Agostini F, Giunciuglio D, Paglieri I, Balansky RM, De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer 1995;61:121-129
12. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002;32:1372-4, 6, 8-9. (Pubitemid 34619770)
13. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-12922 (Pubitemid 37340000)
14. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-1574 (Pubitemid 38428672)
15. Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolo G, Barboro P, Parodi S, Patrone E, Balbi C. Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer. Prostate 2003;55:259-264 (Pubitemid 36618184)
16. Barboro P, Rubagotti A, Boccardo F, Carnemolla B, Darrigo C, Patrone E, Balbi C. Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. Anticancer Res 2005;25:3999-4004. (Pubitemid 41665177)
17. Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 2006;1765:85-100.
18. Ostrowski J, Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 2003;89:1493-1501 (Pubitemid 37386605)
19. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006;95:921-927 (Pubitemid 44498109)
20. Wei CC, Zhang SL, Chen YW, Guo DF, Ingelfinger JR, Bomsztyk K, Chan JS. Heterogeneous nuclear ribonucleoprotein K modulates angiotensinogen gene expression in kidney cells. J Biol Chem 2006;281:25344-25355 (Pubitemid 44401922)
21. Bouquet C, Lamande N, Brand M, Gasc JM, Jullienne B, Faure G, Griscelli F, Opolon P, Connault E, Perricaudet M, Corvol P. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther 2006;14:175-182 (Pubitemid 43942345)
22. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW, Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372
23. Sataranatarajan K, Lee MJ, Mariappan MM, Feliers D. PKCdelta regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K. Cell Signal 2008;20:969-977
24. Inoue A, Sawata SY, Taira K, Wadhwa R. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA 2007;104:8983-8988 (Pubitemid 47175423)
25. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-2735 (Pubitemid 34525751)
26. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-7506 (Pubitemid 32995040)
27. Kamat AA, Kim TJ, Landen CN, Jr., Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-288 (Pubitemid 46142786)
28. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436 (Pubitemid 38745528)
29. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177:2136-2140, 2007; discussion 40. (Pubitemid 46726410)
30. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 2005;5:7. (Pubitemid 40180312)
31. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 2002;8:3910-3921 (Pubitemid 35424786)
32. Takimoto M, Tomonaga T, Matunis M, Avigan M, Krutzsch H, Dreyfuss G, Levens D. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J Biol Chem 1993;268:18249-18258 (Pubitemid 23260350)
33. Moumen A, Masterson P, O'Connor MJ, Jackson SP. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 2005;123:1065-1078 (Pubitemid 41785421)
34. de Hoog CL, Foster LJ, Mann M. RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers. Cell 2004;117:649-662 (Pubitemid 38692530)
35. Brand M, Lamande N, Larger E, Corvol P, Gasc JM. Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J Mol Med 2007;85:451-460 (Pubitemid 46701654)
36. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245
37. Haines I. Docetaxel for hormone-refractory prostate cancer. Lancet 2008;372:1461; author reply 1461-1462